ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MLYS vs TRAX // RETURN ON INVESTED CAPITAL (ROIC)

Mineralys Therapeutics Inc. (NASDAQ) VS. First Tracks Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MLYS 2 — TRAX 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MLYS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MLYS VS. TRAX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MLYS TRAX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -28.40% -35.00% +6.60 MLYS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.58% -7.53% -0.05 TRAX /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 MLYS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.0 66.1 -20.10 TRAX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.88B $1.90B -$22.5M TRAX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MLYS REV TRAX REV MLYS GROSS % TRAX GROSS % MLYS FCF TRAX FCF
FY 2025 $0 $0 — — -$142.4M -$143.0M
FY 2024 $0 $0 — — -$166.3M -$126.2M
FY 2023 $0 — — — -$81.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MLYS // BETA —
TRAX // BETA —